See more : PT Wilmar Cahaya Indonesia Tbk. (PTCXF) Income Statement Analysis – Financial Results
Complete financial analysis of RenovaCare, Inc. (RCAR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of RenovaCare, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Workday, Inc. (0M18.L) Income Statement Analysis – Financial Results
- Right Way Industrial Co.,Ltd (1506.TW) Income Statement Analysis – Financial Results
- Kennametal India Limited (KENNAMET.BO) Income Statement Analysis – Financial Results
- MGM China Holdings Limited (2282.HK) Income Statement Analysis – Financial Results
- PT Utama Radar Cahaya Tbk (RCCC.JK) Income Statement Analysis – Financial Results
RenovaCare, Inc. (RCAR)
About RenovaCare, Inc.
RenovaCare, Inc., a development-stage biotech and medical device company, focuses on the research, development, and commercialization of autologous cellular therapies for use in medical and aesthetic applications. It is developing CellMist System, a treatment methodology for cell isolation for the regeneration of human skin cells; and SkinGun, a solution sprayer device for delivering the cells to the treatment area. RenovaCare, Inc. has a strategic collaboration StemCell Systems GmbH for isolating and spraying self-donated stem cells to regenerate tissues and organs. The company was formerly known as Janus Resources, Inc. and changed its name to RenovaCare, Inc. in January 2014. RenovaCare, Inc. is based in Scottsdale, Arizona.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 19.49K | 32.79K | 39.85K | 51.13K | 13.77K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 919.42K | 463.29K | 153.71K | 0.00 | 66.43K |
| Cost of Revenue | 0.00 | 10.97K | 22.02K | 264.00 | 317.00 | 317.00 | 53.00 | 0.00 | 0.00 | 0.00 | 32.39K | 249.18K | 24.99K | 42.98K | 9.08K | 9.83K | 56.55K | 25.52K | 0.00 | 0.00 | 226.35K | 258.61K | -138.82K | 0.00 | 0.00 |
| Gross Profit | 0.00 | -10.97K | -22.02K | -264.00 | -317.00 | -317.00 | -53.00 | 0.00 | 0.00 | 0.00 | -12.89K | -216.39K | 14.86K | 8.15K | 4.69K | -9.83K | -56.55K | -25.52K | 0.00 | 0.00 | 693.06K | 204.68K | 292.53K | 0.00 | 66.43K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -66.14% | -660.00% | 37.29% | 15.94% | 34.06% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 75.38% | 44.18% | 190.31% | 0.00% | 100.00% |
| Research & Development | 0.00 | 3.20M | 4.13M | 745.95K | 368.95K | 574.09K | 309.50K | 281.22K | 975.67K | 0.00 | 0.00 | 36.85K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 2.20M | 5.54M | 2.94M | 1.64M | 2.12M | 1.59M | 1.04M | 1.16M | 628.55K | 248.60K | 536.09K | 0.00 | 312.16K | 0.00 | 7.95K | 47.68K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 19.29K | 34.16K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 0.00 | 2.20M | 5.54M | 2.94M | 1.64M | 2.12M | 1.59M | 1.04M | 1.16M | 628.55K | 248.60K | 536.09K | 215.46K | 312.16K | 190.69K | 27.24K | 81.84K | 56.54K | 133.67K | 579.71K | 845.67K | 558.77K | 967.59K | 747.99K | 355.02K |
| Other Expenses | 0.00 | 931.28K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 13.33K | 3.26K | 107.16K | 0.00 | 93.44K | 375.00 | 1.06K | 14.17K | 42.96K | 125.32K | 125.32K | 0.00 | 0.00 | 0.00 | 14.34K |
| Operating Expenses | 0.00 | 5.41M | 9.68M | 3.69M | 2.01M | 2.70M | 1.90M | 1.32M | 2.13M | 628.55K | 261.93K | 576.21K | 322.62K | 312.16K | 284.14K | 27.61K | 82.90K | 70.71K | 176.63K | 705.03K | 970.99K | 558.77K | 967.59K | 747.99K | 369.36K |
| Cost & Expenses | 0.00 | 5.41M | 9.68M | 3.69M | 2.01M | 2.70M | 1.90M | 1.32M | 2.13M | 628.55K | 261.93K | 825.39K | 347.61K | 355.15K | 293.22K | 27.61K | 82.90K | 70.71K | 176.63K | 705.03K | 1.20M | 817.38K | 828.77K | 747.99K | 369.36K |
| Interest Income | 0.00 | 6.42K | 128.76K | 332.24K | 22.45K | 3.14K | 1.03K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 14.30K | 2.93K | 1.86K | 2.75K | 1.58K | 5.82K | 16.04K | 36.13K | 86.60K | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 135.27K | 996.65K | 180.70K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 375.00 | 1.06K | 0.00 | 0.00 | 614.00 | 518.00 | 0.00 | 0.00 | 38.33K | 71.06K |
| Depreciation & Amortization | 228.49K | 10.97K | 22.02K | 264.00 | 317.00 | 317.00 | 53.00 | 1.31K | 2.13K | 2.22 | 1.53K | 3.26K | 4.04M | -1.24M | 93.44K | 0.00 | -36.04K | 14.17K | 42.96K | 125.32K | 125.32K | 170.89K | 183.09K | 0.00 | 0.00 |
| EBITDA | 0.00 | -5.40M | -9.53M | -3.36M | -2.01M | -2.70M | -1.90M | -1.32M | -2.13M | -628.55K | -239.38K | -786.07K | 3.65M | -596.92K | -186.00K | -27.61K | -104.23K | -53.80K | -133.67K | -579.71K | -152.61K | -183.21K | -491.98K | -747.99K | -302.93K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,227.96% | -18,420.46% | 9,163.04% | -3,671.87% | -1,350.78% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -16.60% | -39.54% | -320.06% | 0.00% | -456.05% |
| Operating Income | 0.00 | -5.41M | -9.68M | -3.69M | -2.01M | -2.70M | -1.90M | -1.32M | -2.13M | -628.55K | -243.96K | -792.60K | -387.01K | -639.91K | -279.45K | -27.61K | -82.90K | -70.71K | -176.63K | -705.03K | -277.93K | -354.09K | -858.15K | -747.99K | -302.93K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,251.46% | -2,417.42% | -971.25% | -1,251.43% | -2,029.39% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -30.23% | -76.43% | -558.29% | 0.00% | -456.05% |
| Total Other Income/Expenses | 0.00 | 937.69K | 128.76K | 332.24K | -112.82K | -993.52K | -179.67K | 0.00 | 0.00 | 0.00 | 0.00 | 5.25M | -3.88M | 1.91M | 14.30K | 2.55K | 59.23K | 2.75K | 1.58K | 5.21K | 15.52K | 0.00 | 0.00 | 0.00 | 302.93K |
| Income Before Tax | 0.00 | -4.47M | -9.55M | -3.36M | -2.12M | -3.69M | -2.08M | -1.32M | -2.13M | -628.55K | -243.96K | 4.46M | -4.35M | 1.27M | -372.89K | 0.00 | -46.87K | -67.97K | -175.05K | -699.82K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,251.46% | 13,595.58% | -10,906.67% | 2,482.79% | -2,708.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -6.42K | -128.76K | 160.64K | 22.45K | 3.14K | 15.22K | -1.31K | -2.13K | 404.24K | 1.53K | -5.25M | -79.25K | -335.89K | -107.74K | 24.68K | -1.86K | 0.00 | 0.00 | 0.00 | -15.52K | -36.13K | 96.48K | 709.66K | 231.88K |
| Net Income | 0.00 | -4.47M | -9.42M | -3.36M | -2.12M | -3.69M | -2.08M | -1.32M | -2.13M | -1.03M | -243.96K | 4.46M | -4.27M | 1.27M | -265.15K | -24.68K | -45.00K | -67.97K | -175.05K | -699.82K | -262.40K | -317.97K | -771.55K | -709.66K | -231.88K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,251.46% | 13,595.58% | -10,707.79% | 2,482.79% | -1,925.56% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -28.54% | -68.63% | -501.95% | 0.00% | -349.08% |
| EPS | 0.00 | -0.05 | -0.11 | -0.04 | -0.03 | -0.05 | -0.03 | -0.02 | -0.03 | -0.02 | 0.00 | 0.07 | -0.07 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 | -0.02 | -0.03 | -0.07 | -0.03 | -0.01 |
| EPS Diluted | 0.00 | -0.05 | -0.11 | -0.04 | -0.03 | -0.05 | -0.03 | -0.02 | -0.03 | -0.02 | 0.00 | 0.07 | -0.07 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 | -0.02 | -0.03 | -0.07 | -0.03 | -0.01 |
| Weighted Avg Shares Out | 0.00 | 87.35M | 87.35M | 87.24M | 77.75M | 74.39M | 69.77M | 67.23M | 66.58M | 63.40M | 63.08M | 63.08M | 63.08M | 63.08M | 59.37M | 96.52M | 96.63M | 96.63M | 96.63M | 96.63M | 15.98M | 11.80M | 11.80M | 23.24M | 23.05M |
| Weighted Avg Shares Out (Dil) | 0.00 | 87.35M | 87.35M | 87.24M | 77.75M | 74.39M | 69.77M | 67.23M | 66.58M | 63.40M | 63.08M | 63.08M | 63.08M | 63.08M | 59.37M | 96.52M | 96.63M | 96.63M | 96.63M | 96.63M | 15.98M | 11.80M | 11.80M | 23.24M | 23.05M |
RenovaCare Announces Termination of StemCell Systems R&D Agreement
SCOTTSDALE, Ariz., May 03, 2022 (GLOBE NEWSWIRE) -- RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), a clinical-stage developer of patented technologies for isolating and spraying cells for the regeneration of skin and other organs and tissues, today announced the termination of its July...
SHAREHOLDER ALERT: Rigrodsky Law, P.A. is Investigating RenovaCare, Inc.
Wilmington, Delaware--(Newsfile Corp. - April 14, 2022) - Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of RenovaCare, Inc. (OTC Pink: RCAR) on behalf of stockholders.To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-renovacare-inc.To...
RenovaCare Announces Management Changes
SCOTTSDALE, Ariz., March 24, 2022 (GLOBE NEWSWIRE) -- RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), a clinical-stage developer of patented technologies for isolating and spraying cells for the regeneration of skin and other organs and tissues, today announced reductions in its management team...
RenovaCare Provides Clinical and Corporate Update
SCOTTSDALE, Ariz., March 09, 2022 (GLOBE NEWSWIRE) -- RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), a clinical-stage developer of patented technologies for isolating and spraying cells for the regeneration of skin and other organs and tissues, today announced that following the review of...
RM LAW Announces Investigation of RenovaCare, Inc.
BERWYN, Pa. , Feb. 3, 2022 /PRNewswire/ -- RM LAW, P.C.
SHAREHOLDER ALERT: Robbins LLP Investigates RenovaCare, Inc. (RCAR) on Behalf of Investors
SAN DIEGO--(BUSINESS WIRE)---- $RCAR #classaction--RenovaCare, Inc. (RCAR) Charged with Securities Fraud
RENOVACARE ALERT: Bragar Eagel & Squire, P.C. is Investigating RenovaCare, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NEW YORK--(BUSINESS WIRE)-- #Class--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against RenovaCare, Inc. (Other OTC: RCAR) on behalf of long-term stockholders following a class action complaint that was filed against RenovaCare...
RCAR Long-Term Investor Alert: Did You Acquire RenovaCare, Inc. Before August 14, 2017? Should Management be Held Accountable for Investors Losses?
SAN DIEGO, Sept. 16, 2021 /PRNewswire/ -- Johnson Fistel, LLP is investigating potential claims on behalf of RenovaCare, Inc. (OTC: RCAR) against certain of its officers and directors.
Last Few Hours to Actively Participate: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of RenovaCare, Inc. (RCAR) Class Action and Lead Plaintiff Deadline: September 14, 2021
New York, New York--(Newsfile Corp. - September 14, 2021) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against RenovaCare, Inc. (OTC Pink: RCAR) ("RenovaCare" or "the Company") and certain of its officers, on...
Last Few Hours to Actively Participate: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of RenovaCare, Inc. (RCAR) Class Action and Lead Plaintiff Deadline: September 14, 2021
New York, New York--(Newsfile Corp. - September 14, 2021) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against RenovaCare, Inc. (OTC Pink: RCAR) ("RenovaCare" or "the Company") and certain of its officers, on...
Source: https://incomestatements.info
Category: Stock Reports